9 years of historical data (2016–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sutro Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.7B | $141M | $258M | $410M | $686M | $707M | $253M | $206M | — | — |
| Enterprise Value | $1.8B | $155M | $222M | $418M | $713M | $526M | $257M | $96M | — | — |
| P/E Ratio → | -6.92 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 28.08 | 2.28 | 1.68 | 6.05 | 11.09 | 16.55 | 5.91 | 5.37 | — | — |
| P/B Ratio | 35.26 | 3.17 | 1.72 | 1.89 | 2.72 | 2.13 | 2.58 | 1.57 | — | — |
| P/FCF | — | — | — | — | — | — | — | 18.54 | — | — |
| P/OCF | — | — | — | 115.52 | — | — | — | 16.26 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.50 | 1.45 | 6.16 | 11.53 | 12.30 | 6.02 | 2.49 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 8.60 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Sutro Biopharma, Inc. earns an operating margin of -384.3%. Operating margins have compressed from -190.3% to -384.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -234.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.4% | 88.4% | 95.6% | 87.8% | 84.2% | -80.1% | 100.0% | -41.2% | -0.3% | 27.1% |
| Operating Margin | -384.3% | -384.3% | -58.1% | -190.3% | -159.2% | -166.3% | -129.8% | -96.9% | -37.2% | 2.3% |
| Net Profit Margin | -366.6% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | -130.4% | -91.9% | -38.1% | 2.8% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -234.2% | -234.2% | -58.2% | -50.8% | -36.1% | -14.9% | -48.6% | -313.4% | — | — |
| ROA | -53.0% | -53.0% | -24.3% | -31.9% | -28.7% | -11.7% | -29.4% | -26.8% | -35.8% | 2.5% |
| ROIC | -207.6% | -207.6% | -39.5% | -38.4% | -34.4% | -42.1% | -67.3% | — | — | — |
| ROCE | -75.4% | -75.4% | -24.9% | -40.3% | -29.7% | -29.1% | -35.8% | -38.1% | -138.1% | 7.1% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $14M ($204M total debt minus $190M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 4.57 | 4.57 | 0.22 | 0.25 | 0.23 | 0.07 | 0.10 | 0.11 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.17 |
| Net Debt / Equity | — | 0.31 | -0.24 | 0.04 | 0.11 | -0.55 | 0.05 | -0.84 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -1.48 |
| Debt / FCF | — | — | — | — | — | — | — | -9.94 | — | — |
| Interest Coverage | -7.67 | -7.67 | -3.76 | -38.54 | -31.41 | -17.88 | -12.75 | -23.26 | -27.97 | — |
Short-term solvency ratios and asset-utilisation metrics
Sutro Biopharma, Inc.'s current ratio of 2.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.31x to 2.60x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.60 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
| Quick Ratio | 2.60 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
| Cash Ratio | 2.40 | 2.40 | 4.01 | 5.02 | 4.74 | 12.44 | 3.58 | 5.61 | 0.69 | 0.95 |
| Asset Turnover | — | 0.16 | 0.33 | 0.17 | 0.18 | 0.11 | 0.27 | 0.17 | 1.27 | 0.86 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 50.69 | 85.66 | 38.36 | 73.46 | 47.49 | 53.79 | 23.65 | 11.46 | 3.53 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sutro Biopharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 5.4% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Shares Outstanding | — | $77M | $60M | $51M | $46M | $33M | $23M | $23M | $7M | $441201 |
Compare STRO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| STROYou | $2B | -6.9 | — | — | 88.4% | -384.3% | -234.2% | -207.6% | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 9 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how STRO stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonSutro Biopharma, Inc.'s current P/E ratio is -6.9x. This places it at the 50th percentile of its historical range.
Sutro Biopharma, Inc.'s return on equity (ROE) is -234.2%. The historical average is -108.0%.
Based on historical data, Sutro Biopharma, Inc. is trading at a P/E of -6.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Sutro Biopharma, Inc. has 88.4% gross margin and -384.3% operating margin.